Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.66 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.64 |
| ▸ | CMA1 | P23946 | 10/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.57 |
| ▸ | CTRC | Q99895 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7087290 | 1.00 | ACE (0.66) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL6412055 | 1.00 | ACE (0.66) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL3692081 | 0.92 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL5900839 | 0.92 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL22409423 | 0.92 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL3692085 | 0.92 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL8378100 | 0.92 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL5900836 | 0.92 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL8891583 | 0.91 | ACE (0.55) | ACEF2PRSS1CMA1CTRC | |
| SCHEMBL16576478 | 0.90 | F2 (0.65) | ACEF2PRSS1CMA1KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | ACE 5/4885F2 3521/4885PRSS1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.